University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Kathryn A. Phillips, PhD, MPA

Kathryn A. Phillips, PhD, MPA

Professor of Health Services Research and Health Economics, Department of Clinical Pharmacy, School of Pharmacy; Director/Founder, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), UCSF

Cancer Center Program Memberships

Cancer Control

Research Summary

My research focuses on the value of new technologies, with a specific emphasis on the application of genetics to cancer care and control (“personalized medicine”). In 2008, I founded the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), which focuses on how personalized medicine can be most effectively and efficiently be adopted into health care delivery and health policies. I have had continuous funding from the NIH as Principal Investigator for over 20 years, have led or participated in over 50 funded research grants, and have published over 100 peer-reviewed articles in all of the leading journals in health policy. A particular focus is cross-disciplinary/cross-sector research as exemplified by my advisory role to many government and industry organizations.
My work in cancer screening spans almost my entire academic career, with early work on predictors of mammography screening followed by work on colorectal cancer screening. I now work on policy issues relevant to hereditary cancer risk assessment testing and tumor profiling using sequencing technologies. I work closely with the UCSF HDFCCC as a long-time member of the Population Sciences/Cancer Control Program and as the designated leader for comparative effectiveness research. I have presented at multiple IOM, NCI, and other meetings focused on cancer and have published in leading cancer journals. My work has been funded by several cancer organizations, including two R01s and a Program Project Grant (P01) funded by NCI.

Education

University of Texas, Austin, BA, 1978, Psychology
Kennedy School of Government, Harvard Univ., Cambridge, MA, MPA, 1986, Policy Analysis
University of California, Berkeley, PhD, 1991, Health Services Research
Center for AIDS Prevention Studies, Univ. of CA San Francisco, Postdoc, 1993, Health Services Research


Professional Experience

  • 1993-1995
    Assistant Research Professor, University of California, San Francisco (UCSF)
  • 1995-1998
    Assistant Professor (non-tenure track), UCSF
  • 1998-2004
    Associate Professor of Health Economics and Health Services Research, UCSF
  • 2007
    Visiting Scholar, Harvard Partners Center for Genetics and Genomics and New England Health Care Institute, Boston, MA
  • 2004-present
    Professor of Health Economics and Health Services Research (tenured) and Director/Founder, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, School of Pharmacy (home department); Institute for Health Policy Studies & UCSF Comprehensive Cancer Center (affiliated faculty) University of California, San Francisco

Honors & Awards

  • 1977
    Phi Beta Kappa
  • 1985-1986
    Long-Term Civilian Training Award for study at Harvard University, Department of Navy
  • 1987
    Special Achievement Award, Federal Aviation Administration
  • 1987-1988
    University of California-Berkeley Graduate Fellowship
  • 1989
    Outstanding Graduate Student Instructor, University of California-Berkeley
  • 2003
    Named as one of the "50 Most Cited HIV Behavioral Researchers in the Past Decade"
  • 2006
    Nominated to HHS Secretary’s Advisory Committee on Genetics, Health, and Society
  • 2009
    Grollman Lecture at the University of Maryland School of Pharmacy
  • 2010
    Director’s Lecture, National Human Genome Research Institute (NHGRI)

Selected Publications

  1. Phillips KA, Marshall DA, Kurian AW. Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits? Per Med. 2019 Sep 25.
    View on PubMed
  2. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2019 Sep 10.
    View on PubMed
  3. Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019 May 30.
    View on PubMed
  4. Phillips KA. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value Health. 2018 09; 21(9):1031-1032.
    View on PubMed
  5. Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value Health. 2018 09; 21(9):1054-1061.
    View on PubMed
  6. Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Value Health. 2018 09; 21(9):1033-1042.
    View on PubMed
  7. Trosman JR, Weldon CB, Gradishar WJ, Benson AB, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018 09; 21(9):1062-1068.
    View on PubMed
  8. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2019 01; 21(1):152-160.
    View on PubMed
  9. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018 06 19; 319(23):2379-2380.
    View on PubMed
  10. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 05; 37(5):710-716.
    View on PubMed
  11. Ginsburg GS, Phillips KA. Precision Medicine: From Science To Value. Health Aff (Millwood). 2018 05; 37(5):694-701.
    View on PubMed
  12. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018 Apr 20; 360(6386):278-279.
    View on PubMed
  13. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553.
    View on PubMed
  14. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 01; 20(1):165.
    View on PubMed
  15. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540.
    View on PubMed
  16. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 07 12; 35(7):614-617.
    View on PubMed
  17. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211.
    View on PubMed
  18. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 10; 19(10):1081-1091.
    View on PubMed
  19. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228.
    View on PubMed
  20. Phillips KA, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53.
    View on PubMed

Go to UCSF Profiles, powered by CTSI